Objective Peripheral Nerve Injuries (PNIs) are lesions of the nerves of the head or the extremities. Grand View Research estimates over 2 million cases of PNIs per year in the EU and the USA. These injuries remain incurable, resulting in permanent loss of body function as in paraplegia, leading to disabilities and heavy social burden. The chance to cure PNIs based on smart nano-engineered biomaterials will have a major positive impact in heavy and long term burdens on patients and healthcare systems. In this context, Nerve Biomed’s team, a spin-off company of the Polytechnic University of Valencia (Spain) has been leading an R&D initiative in advanced PNI reparation over the past 11 years, in order to develop and further commercialise ULTRANERVE: an easy-to-use medical solution for PNI regeneration, which is going to simplify medical procedures and reduce the average full recovery time, while decreasing significantly the average cost of actual repair procedures.Within the roadmap established by the company to commercialize the product internationally by 2020, Nerve Biomed wants to perform a thorough feasibility study, through this SME Instrument Phase 1, which will assess in detail the practical and economic viability of introducing this solution in the PNI repair and regeneration market ih the EU and the USA. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinephysiotherapymedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineneurology Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator NERVE BIOMED SOCIEDAD LIMITADA Net EU contribution € 50 000,00 Address CALLE CANONIGO MOLINA ALONSO, NUM. 6 04004 ALMERIA Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Sur Andalucía Almería Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
